248 related articles for article (PubMed ID: 28771657)
41. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
42. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
Hjalte F; Carlsson KS; Schmitt-Egenolf M
Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
[TBL] [Abstract][Full Text] [Related]
43. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life.
Walker F; Adamczyk A; Kellerer C; Belge K; Brück J; Berner T; Merten K; Núnez Gómez N; Neureither M; Röcken M; Ghoreschi K;
Br J Dermatol; 2014 Nov; 171(5):1197-205. PubMed ID: 24813676
[TBL] [Abstract][Full Text] [Related]
44. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
45. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
46. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
[TBL] [Abstract][Full Text] [Related]
47. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
[TBL] [Abstract][Full Text] [Related]
48. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
49. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
50. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.
Armstrong AW; Feldman SR; Korman NJ; Meng X; Guana A; Nyirady J; Herrera V; Zhao Y
J Dermatolog Treat; 2017 May; 28(3):200-205. PubMed ID: 27541729
[TBL] [Abstract][Full Text] [Related]
51. Assessment of Life Quality Index and Treatment Efficacy in Psoriasis Vulgaris Patients Receiving Biologic Therapies in a Turkish Population.
Gundogdu M; Kundakci N; Erdem C
Skinmed; 2020; 18(2):84-90. PubMed ID: 32501790
[TBL] [Abstract][Full Text] [Related]
52. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
[TBL] [Abstract][Full Text] [Related]
53. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
[TBL] [Abstract][Full Text] [Related]
54. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.
Paul C; Guenther L; Torii H; Sofen H; Burge R; Lin CY; Potts Bleakman A; Mallbris L; Poulin Y
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):68-72. PubMed ID: 28881462
[TBL] [Abstract][Full Text] [Related]
55. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
Bergstrom KG; Arambula K; Kimball AB
Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
[TBL] [Abstract][Full Text] [Related]
56. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
Leonardi C; Maari C; Philipp S; Goldblum O; Zhang L; Burkhardt N; Ball S; Mallbris L; Gonzalez P; Fernández-Peñas P; Puig L
J Am Acad Dermatol; 2018 Nov; 79(5):824-830.e2. PubMed ID: 29803904
[TBL] [Abstract][Full Text] [Related]
57. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
[TBL] [Abstract][Full Text] [Related]
58. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
60. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
